Drugs / BxC-I17e
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06055374 | May 2024 → Apr 2025 | atopic eczema | Brexogen Inc. | Withdrawn | No outcome recorded |
| Phase 1 | NCT06055361 | Apr 2023 → Mar 2026 overdue | atopic eczema | Brexogen Inc. | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BxC-I17e | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06055374 ↗ |
| Modality | Other / unclassified | “primed iMSC derived Extracellular vesicles(EV)” NCT06055361 ↗ |
| Route | Subcutaneous | “Administered Subcutaneously in Patients With Moderate to Severe Atopic Dermatitis” NCT06055361 ↗ |